• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Galecto Inc.

    4/30/25 4:00:04 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    DEFA14A 1 defa-14a_-_2025_proxy_no.htm DEFA14A DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934 (Amendment No. )

     

     

    Filed by the Registrant ☒

     

    Filed by a Party other than the Registrant 

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Under Rule 14a-12

     

    GALECTO, INC.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     


     

     

    img65807404_0.jpg

     

    Your Vote Counts! GALECTO, INC. 2025 Annual Meeting Vote by June 17, 2025 11:59 PM ET Galecto GALECTO, INC 75 STATE STREET, SUITE 100 BOSTON, MA 02109 ATTN: GARRETT WINSLOW V72395-P31801 You invested in GALECTO, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 18, 2025. Get informed before you vote View the Notice and Proxy Statement and Annual Report to Stockholders online OR you can receive a free paper or email copy of the material(s) by requesting prior to June 4, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 18, 2025 9:00 a.m., Eastern Time Virtually at: www.virtualshareholdermeeting.com/GLTO2025 *Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img65807404_1.jpg

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1. Election of Directors Nominees: 01) Carl Goldfischer, M.D. 02) David Shapiro, M.D. 2. Approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company’s Common Stock upon conversion of the Company’s issued and outstanding Series A Preferred Stock. 3. Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the independent registered public accounting firm for the fiscal year ending December 31, 2025. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. For For For Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V72396-P31801

     


    Get the next $GLTO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Galecto Reports Full-Year 2024 Financial Results

      Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge MedicinesGB3226 on track for IND submission in Q1 2026Phase 2 investigator-initiated trial (IIT) of GB1211 in combination with pembrolizumab (Keytruda®) in metastatic melanoma and head and neck squamous cell carcinoma continues to enroll patients BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced its operating and financial r

      3/19/25 4:45:00 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Participate in Upcoming Investor Conferences

      BOSTON, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today announced that the Company management team will participate in the following upcoming investor conferences: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFormat: Corporate Presentation and One-on-One MeetingsDate and Time: Wednesday, February 12 at 8:40-9:10 AM   Location: Virtual A live webcast of the presentation will be available via the Upcoming Events section of the Company's investor relations website at https://ir.galecto.com/news-and-events/events. An archived replay wi

      2/6/25 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Reports Third Quarter 2024 Financial Results

      -  Completed strategic review to focus on oncology and severe liver diseases -  Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines -  Appointed Dr. Amy Wechsler to the Board of Directors and Matthew Kronmiller as Executive Vice President of Strategy and Chief Business Officer BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and severe liver diseases, today reported financial results for the third quarter ended September 30, 2024. "The third quarter was a pivotal perio

      11/1/24 8:30:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    See more
    • Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

      BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

      10/15/24 8:30:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Adds Experienced Biotech Executive Stephanie Oestreich as Chief Business Officer

      BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto. Dr. Oestreich joins Galecto from Mnemo Therapeutics where she served as Vice President of Operations and Head of Alliance Management. She previously held the role of Executive Vice President at Evotec, a biotech company focusing on developing and delivering new medicines, and has previously served in a number of senior roles

      1/5/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Appoints Garrett Winslow as General Counsel

      BOSTON, May 11, 2021 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel. In this role, Mr. Winslow will lead the Company's legal, compliance and enterprise risk management functions, reporting to Hans Schambye, CEO. Garrett Winslow brings to Galecto over 15 years of experience working with public companies in the life sciences industry. Prior to joining Galecto, he served as the General Counsel of Spring Bank Pharmaceuticals.  He was also a partner in the Corporate and Securitie

      5/11/21 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Financials

    Live finance-specific insights

    See more
    • Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

      Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

      10/7/24 8:45:46 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

      Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

      11/8/22 6:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

      Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

      10/31/22 8:00:00 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse reiterated coverage on Galecto with a new price target

      Credit Suisse reiterated coverage of Galecto with a rating of Outperform and set a new price target of $7.00 from $12.00 previously

      8/6/21 10:59:40 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on Galecto with a new price target

      Credit Suisse resumed coverage of Galecto with a rating of Outperform and set a new price target of $12.00

      4/26/21 8:53:50 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse Group reiterated coverage on Galecto with a new price target

      Credit Suisse Group reiterated coverage of Galecto with a rating of Outperform and set a new price target of $12.00 from $29.00 previously

      3/16/21 8:17:33 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel Winslow Garrett converted options into 1,320 shares and sold $2,638 worth of shares (471 units at $5.60), increasing direct ownership by 531% to 1,009 units (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:07 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Schambye Hans T. converted options into 2,640 shares and sold $7,510 worth of shares (1,341 units at $5.60), increasing direct ownership by 62% to 3,397 units (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:03 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Interim CFO Firmani Lori converted options into 726 shares and sold $1,469 worth of shares (261 units at $5.63) (SEC Form 4)

      4 - Galecto, Inc. (0001800315) (Issuer)

      1/7/25 4:00:06 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Galecto Inc.

      DEFA14A - Galecto, Inc. (0001800315) (Filer)

      4/30/25 4:00:04 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Galecto Inc.

      DEF 14A - Galecto, Inc. (0001800315) (Filer)

      4/30/25 7:00:10 AM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Galecto Inc.

      PRE 14A - Galecto, Inc. (0001800315) (Filer)

      4/17/25 4:00:10 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      11/7/24 3:07:49 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Galecto Inc.

      SC 13G - Galecto, Inc. (0001800315) (Subject)

      11/7/24 2:55:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Galecto Inc.

      SC 13G/A - Galecto, Inc. (0001800315) (Subject)

      8/29/24 5:59:56 PM ET
      $GLTO
      Biotechnology: Pharmaceutical Preparations
      Health Care